Chu et al., reported that the dual kinase inhibitor Laptinib for HER2 and EGFR cooperates with tamoxifen to inhibit cell proliferation in antiestrogen resistant breast cancer [19]. The gene discussed is ERBB2; the disease is breast carcinoma.